Publikation:

Immunoproteasome inhibition attenuates experimental psoriasis

Lade...
Vorschaubild

Dateien

DelRioOliva_2-vuy7lolf6jkg8.pdf
DelRioOliva_2-vuy7lolf6jkg8.pdfGröße: 8.58 MBDownloads: 95

Datum

2022

Autor:innen

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Gold
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Frontiers in Immunology. Frontiers Media. 2022, 13, 1075615. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2022.1075615

Zusammenfassung

Introduction: Psoriasis is an autoimmune skin disease associated with multiple comorbidities. The immunoproteasome is a special form of the proteasome expressed in cells of hematopoietic origin.

Methods: The therapeutic use of ONX 0914, a selective inhibitor of the immunoproteasome, was investigated in Card14ΔE138+/- mice, which spontaneously develop psoriasis-like symptoms, and in the imiquimod murine model.

Results: In both models, treatment with ONX 0914 significantly reduced skin thickness, inflammation scores, and pathological lesions in the analyzed skin tissue. Furthermore, immunoproteasome inhibition normalized the expression of several pro-inflammatory genes in the ear and significantly reduced the inflammatory infiltrate, accompanied by a significant alteration in the αβ+ and γδ+ T cell subsets.

Discussion: ONX 0914 ameliorated psoriasis-like symptoms in two different murine psoriasis models, which supports the use of immunoproteasome inhibitors as a therapeutic treatment in psoriasis.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

immunoproteasome inhibition, psoriasis, CARD14, imiquimod, ONX 0914

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690DEL RIO OLIVA, Marta, Mark MELLETT, Michael BASLER, 2022. Immunoproteasome inhibition attenuates experimental psoriasis. In: Frontiers in Immunology. Frontiers Media. 2022, 13, 1075615. eISSN 1664-3224. Available under: doi: 10.3389/fimmu.2022.1075615
BibTex
@article{DelRioOliva2022-12-14Immun-59567,
  year={2022},
  doi={10.3389/fimmu.2022.1075615},
  title={Immunoproteasome inhibition attenuates experimental psoriasis},
  volume={13},
  journal={Frontiers in Immunology},
  author={Del Rio Oliva, Marta and Mellett, Mark and Basler, Michael},
  note={German Research Foundation (DFG) grant GR 1517/27-1 and SFB969 project C01

Corrigendum: https://doi.org/10.3389/fimmu.2023.1335691 Article Number: 1075615}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/59567">
    <dcterms:abstract xml:lang="eng">Introduction: Psoriasis is an autoimmune skin disease associated with multiple comorbidities. The immunoproteasome is a special form of the proteasome expressed in cells of hematopoietic origin.&lt;br /&gt;&lt;br /&gt;Methods: The therapeutic use of ONX 0914, a selective inhibitor of the immunoproteasome, was investigated in Card14ΔE138&lt;sup&gt;+/-&lt;/sup&gt; mice, which spontaneously develop psoriasis-like symptoms, and in the imiquimod murine model.&lt;br /&gt;&lt;br /&gt;Results: In both models, treatment with ONX 0914 significantly reduced skin thickness, inflammation scores, and pathological lesions in the analyzed skin tissue. Furthermore, immunoproteasome inhibition normalized the expression of several pro-inflammatory genes in the ear and significantly reduced the inflammatory infiltrate, accompanied by a significant alteration in the αβ&lt;sup&gt;+&lt;/sup&gt; and γδ&lt;sup&gt;+&lt;/sup&gt; T cell subsets.&lt;br /&gt;&lt;br /&gt;Discussion: ONX 0914 ameliorated psoriasis-like symptoms in two different murine psoriasis models, which supports the use of immunoproteasome inhibitors as a therapeutic treatment in psoriasis.</dcterms:abstract>
    <dc:creator>Del Rio Oliva, Marta</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-12-20T10:11:38Z</dcterms:available>
    <dcterms:title>Immunoproteasome inhibition attenuates experimental psoriasis</dcterms:title>
    <dc:language>eng</dc:language>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/59567"/>
    <dc:contributor>Del Rio Oliva, Marta</dc:contributor>
    <dcterms:issued>2022-12-14</dcterms:issued>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-12-20T10:11:38Z</dc:date>
    <dc:contributor>Mellett, Mark</dc:contributor>
    <dc:creator>Basler, Michael</dc:creator>
    <dc:creator>Mellett, Mark</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/59567/1/DelRioOliva_2-vuy7lolf6jkg8.pdf"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/59567/1/DelRioOliva_2-vuy7lolf6jkg8.pdf"/>
    <dc:contributor>Basler, Michael</dc:contributor>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

German Research Foundation (DFG) grant GR 1517/27-1 and SFB969 project C01 Corrigendum: https://doi.org/10.3389/fimmu.2023.1335691
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen